Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
L Emmett, K Willowson, J Violet, J Shin… - Journal of medical …, 2017 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
A Dash, MRA Pillai, FF Knapp - Nuclear medicine and molecular imaging, 2015 - Springer
Background: This review provides a comprehensive summary of the production of 177 Lu to
meet expected future research and clinical demands. Availability of options represents the …
meet expected future research and clinical demands. Availability of options represents the …
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with …
J Violet, P Jackson, J Ferdinandus… - Journal of Nuclear …, 2019 - Soc Nuclear Med
177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …
ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin …
The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy
M Ljungberg, A Celler, MW Konijnenberg… - Journal of nuclear …, 2016 - Soc Nuclear Med
The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is
directly related to the accuracy of the activity (or activity concentration) estimates obtained at …
directly related to the accuracy of the activity (or activity concentration) estimates obtained at …
MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy
In internal radionuclide therapy, a growing interest in voxel-level estimates of tissue-
absorbed dose has been driven by the desire to report radiobiologic quantities that account …
absorbed dose has been driven by the desire to report radiobiologic quantities that account …
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
A Sundlöv, K Sjögreen-Gleisner, J Svensson… - European journal of …, 2017 - Springer
Purpose To present data from an interim analysis of a Phase II trial designed to determine
the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by …
the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by …
Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions
S Okamoto, A Thieme, J Allmann… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …